Business

AstraZeneca has entered into a multi-year agreement with Galapagos subsidiaries BioFocus and Argenta to collaborate on discovery of compounds for the treatment of respiratory and inflammatory diseases. The deal allows AstraZeneca the use of Argenta's respiratory models, including those for asthma, COPD, and inflammation. The companies did not disclose the financial … [Read more...] about Argenta to provide respiratory modeling service to AstraZeneca

Alexza Pharmaceuticals, whose lead product, Adasuve Staccato loxapine is under review by the FDA and the EMA, has reported a net loss of $40.5 million for the year ended December 31, 2011. The company also announced that Grupo Ferrer, its partner on Adasuve in Europe and Latin America, has purchased stock in Alexza in lieu of a potential future milestone payment. … [Read more...] about Alexza reports loss of $40.5 million for 2011, reworks agreement with Grupo Ferrer

Nycomed says that it is now marketing its Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis in the United Arab Emirates (UAE). The company, a subsidiary of Takeda, says that it will launch Omnaris in other Middle East countries by the end of 2012. According to a recent survey sponsored by Nycomed, allergic rhinitis affects over a third of UAE … [Read more...] about Nycomed launches Omnaris nasal spray in the Middle East

Specialty pharmaceutical manufacturer Hi-Tech Pharmacal will pay a total of $2.5 million plus up to to $1.75 million in royalties to Dynova Laboratories for a line of homeopathic nasal sprays including the Sinus Buster and Allergy Buster brands, which Hi-Tech will sell through its Health Care Products OTC division. The Sinus Buster formulation includes capsaicin, and … [Read more...] about Hi-Tech Pharmacal acquires line of homeopathic nasal sprays

On March 1, Judge John Koeltl of the US District Court for the Southern District of New York issued a partial summary judgment in Mylan's patent infringement suit against Sunovion Pharmaceuticals, invalidating 5 of the 7 patents regarding Brovana arformoterol tartrate inhalation solution cited in the suit filed by Mylan's subsidiary Dey against Sunovion (formerly … [Read more...] about Mylan to appeal invalidation of inhalation solution patents

A company called GSC Products has launched what it says is "the world's first caffeine nasal spray" in the US. GSC says that the product, called Turbo Snort, was introduced on the Internet in January and is now sold in more than 500 independent convenience stores. GSC CEO Wayne Perry said, "By delivering caffeine through the nose, it bypasses the systemic processes … [Read more...] about Caffeine nasal spray launched in US

Aradigm has announced that the United States Patent and Trademark Office has issued an additional patent covering several formulations of ciprofloxacin, including the company's lead product, Pulmaquin dual release ciprofloxacin for inhalation. The patent (US Patent No. 8,119,156) will provide exclusivity for Pulmaquin until October 22, 2028. The company, which … [Read more...] about US Patent Office issues new patent for Aradigm’s Pulmaquin

Irish nebulizer manufacturer Aerogen has received authorization from the Chinese State Food and Drug Administration (SFDA) to market its Aeroneb Pro and Aeroneb Go vibrating mesh nebulizers in China. The company expects to begin selling the products in the country by March 2012, with distributed handled by Gaelmed. Aerogen currently markets products in 65 countries. … [Read more...] about Aerogen authorized to market nebulizers in China

Alexza Pharmaceuticals, which is developing a number of inhaled drugs using its proprietary Staccato inhaler, will offer 44,000,000 shares of common stock and 44,000,000 warrants to purchase common stock at $0.50 per share for a total offer of $22 million. One warrant to purchase a common share will be sold with each common share. According to the company, the money … [Read more...] about Alexza offers common stock and warrants